Skip to main content

Jim Cramer on Biogen Earnings, Alzheimer's Drug

Publish date:
Video Rating:
Video Duration:

Biogen  (BIIB) - Get Free Report reported adjusted earnings of $5.68 on revenue of over $2.77 billion. In focus for Jim Cramer, however, was the company's controversial Alzheimer's drug Adhulem. 

According to Biogen's earnings report, the drug generated $2 million in revenue in the first few weeks of its approval. 

In the video above, Cramer explains his criticism of the drug and what he thinks the approval says about the FDA. 

Recap TheStreet Live: Everything Jim Cramer Is Watching 7/22/21

Find out what Cramer is only telling members of his Action Alerts PLUS charitable portfolio in Thursday's Daily Rundown. 

Related Videos